The US Food and Drug Administration (FDA) has given authorisation for a Phase II clinical trial to evaluate psychedelic-assisted psychotherapy for frontline clinicians who are experiencing...
Findings from a new study give insight into how psychedelic substances may relieve symptoms of mental health conditions.
Clearmind Medicine has signed an R&D agreement with Bar-Ilan University to explore the efficacy of its compound for the treatment of addiction.
New findings from a citizen science study suggest that microdosing psychedelics could be a valuable tool in the battle against poor mental health.
A new study has been launched to investigate the effects of LSD microdosing on sleep and cognitive measures.
A study undertaken over a five-year period has shown that a single dose of ketamine improved thinking and reasoning in people who had expressed thoughts of...
A small study has reported that two doses of psilocybin received with supportive psychotherapy relieves depression.
For the multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX) sponsored by MAPS, Numinus will manage two new clinics in Montreal and Vancouver.
The largest psilocybin therapy clinical trial ever conducted, investigating psilocybin for treatment-resistant depression (TRD), has achieved its primary endpoint.
Kicking off the Microdose Wonderland conference in Miami, Cybin Inc announced it will be moving its psilocybin analogue – CYB003 – into clinical trials.
